Please Wait
Applying Filters...
menu
    • menu
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Pegcetacoplan

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Sobi Gets EU Approval For Aspaveli In C3G And Primary IC-MPGN
    Sobi Gets EU Approval For Aspaveli In C3G And Primary IC-MPGN

    16 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/sobi-receives-european-commission-approval-for-aspaveli-pegcetacoplan-for-the-treatment-of-c3g-and-primary-ic-mpgn-302663349.html

    PR NEWSWIRE
    16 Jan 2026
    Share Share
    Enable Injections Secures Saudi Approval For EMPAVELI Injector
    Enable Injections Secures Saudi Approval For EMPAVELI Injector

    18 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/18/3207601/0/en/Enable-Injections-Announces-Regulatory-Approval-in-Saudi-Arabia-for-the-EMPAVELI-Injector-based-on-enFuse-Technology.html

    GLOBENEWSWIRE
    18 Dec 2025
    Share Share
    Sobi Gets CHMP Nod For Aspaveli In C3G And Primary IC-MPGN
    Sobi Gets CHMP Nod For Aspaveli In C3G And Primary IC-MPGN

    12 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/sobi-receives-positive-chmp-opinion-for-aspaveli-pegcetacoplan-for-the-treatment-of-c3g-and-primary-ic-mpgn-302640183.html

    PR NEWSWIRE
    12 Dec 2025
    Share Share
    Sobi Highlights Haematology Commitment At ASH 2025
    Sobi Highlights Haematology Commitment At ASH 2025

    05 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/sobi-to-showcase-scientific-advances-and-commitment-to-haematology-at-ash-2025-302634280.html

    PR NEWSWIRE
    05 Dec 2025
    Share Share
    VALIANT Pharma Reports Positive Phase 3 Results
    VALIANT Pharma Reports Positive Phase 3 Results

    04 Dec 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-12-04/the-new-england-journal-of-medicine-publishes-positive-phase-3-valiant-results-of-pegcetacoplan-for-c3g-and-primary-ic-mpgn

    PHARMIWEB
    04 Dec 2025
    Share Share
    NEJM Publishes VALIANT EMPAVELI Results for C3G & Primary IC-MPGN
    NEJM Publishes VALIANT EMPAVELI Results for C3G & Primary IC-MPGN

    03 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/03/3199410/0/en/The-New-England-Journal-of-Medicine-Publishes-Positive-Phase-3-VALIANT-Results-of-EMPAVELI-pegcetacoplan-for-C3G-and-Primary-IC-MPGN.html

    GLOBENEWSWIRE
    03 Dec 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.